ArticleJournal of virology2003
Link between genome packaging and rate of budding for Rous sarcoma virus.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- ALV-miRNA-p19-01 Promotes Viral Replication via Targeting Dual Specificity Phosphatase 6.Viruses · 2022Article
- An Infectious Rous Sarcoma Virus Gag Mutant That Is Defective in Nuclear Cycling.Journal of virology · 2021Article
- Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.Journal of virology · 2016Article
- Membrane interaction of retroviral Gag proteins.Frontiers in microbiology · 2014Review
- Effect of multimerization on membrane association of Rous sarcoma virus and HIV-1 matrix domain proteins.Journal of virology · 2013Article
- Alterations in the MA and NC domains modulate phosphoinositide-dependent plasma membrane localization of the Rous sarcoma virus Gag protein.Journal of virology · 2013Article
- CRM1-dependent trafficking of retroviral Gag proteins revisited.Journal of virology · 2012Article
- Cytoplasmic utilization of human immunodeficiency virus type 1 genomic RNA is not dependent on a nuclear interaction with gag.Journal of virology · 2012Article
- Rous sarcoma virus gag has no specific requirement for phosphatidylinositol-(4,5)-bisphosphate for plasma membrane association in vivo or for liposome interaction in vitro.Journal of virology · 2011Article
- Structural determinants and mechanism of HIV-1 genome packaging.Journal of molecular biology · 2011Review
- Directionality of nucleocytoplasmic transport of the retroviral gag protein depends on sequential binding of karyopherins and viral RNA.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Quantitative fluorescence resonance energy transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-Gag interaction: relative contributions of the CA and NC domains and membrane binding.Journal of virology · 2009Article
- Genetic evidence for a connection between Rous sarcoma virus gag nuclear trafficking and genomic RNA packaging.Journal of virology · 2009Article
- Cooperative role of the MHR and the CA dimerization helix in the maturation of the functional retrovirus capsid.Virology · 2008Article
- A molecular switch required for retrovirus assembly participates in the hexagonal immature lattice.The EMBO journal · 2008Article
- Intermolecular interactions between retroviral Gag proteins in the nucleus.Journal of virology · 2008Article
- Overlapping roles of the Rous sarcoma virus Gag p10 domain in nuclear export and virion core morphology.Journal of virology · 2007Article
- Mutations that mimic phosphorylation of the HIV-1 matrix protein do not perturb the myristyl switch.Protein science : a publication of the Protein Society · 2007Article
- Genetic Studies of the beta-hairpin loop of Rous sarcoma virus capsid protein.Journal of virology · 2007Article
- Importin-beta family members mediate alpharetrovirus gag nuclear entry via interactions with matrix and nucleocapsid.Journal of virology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The subcellular location at which genomic RNA is packaged by Gag proteins during retrovirus assembly remains unknown. Since the membrane-binding (M) domain is most critical for targeting Gag to the plasma membrane, changes to this determinant might alter the path taken through the cell and reduce the efficiency of genome packaging. In this report, a Rous sarcoma virus (RSV) mutant having two acidic-to-basic substitutions in the M domain is described. This mutant, designated Super M, produced particles much faster than the wild type, but the mutant virions were noninfectious and contained only 1/10 the amount of genomic RNA found in wild-type particles. To identify the cause(s) of these defects, we considered data that suggest that RSV Gag traffics through the nucleus to package the viral genome. Although inhibition of the CRM-1 pathway of nuclear export caused the accumulation of wild-type Gag in the nucleus, nuclear accumulation did not occur with Super M. The importance of the nucleocapsid (NC) domain in membrane targeting was also determined, and, importantly, deletion of the NC sequence prevented plasma membrane localization by wild-type Gag but not by Super M Gag. Based on these results, we reasoned that the enhanced membrane-targeting properties of Super M inhibit genome packaging. Consistent with this interpretation, substitutions that reestablished the wild-type number of basic and acidic residues in the Super M Gag M domain reduced the budding efficiency and restored genome packaging and infectivity. Therefore, these data suggest that Gag targeting and genome packaging are normally linked to ensure that RSV particles contain viral RNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.